Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1Phase 1/2 1

Status

Completed 5Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 1Classical hematology 1

Conditions

Pain 19Neoplasms 18Cancer Pain 6Breast Neoplasms 5Breakthrough Pain 5Prostatic Neoplasms 4Lung Neoplasms 4Colonic Neoplasms 4Agnosia 4Rectal Neoplasms 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Chronic Pain 3Uterine Cervical Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pain, Postoperative 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Burns 2Anemia, Sickle Cell 2post laminectomy syndrome 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1

Interventions

Fentanyl 5Morphine 2Urinary Catheterization 1Ultracet 1Patient Positioning 1Methadone 1Gastrostomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Breakthrough Pain × Fentanyl × Clear all
NCT00263575 2024-06-18

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Kyowa Kirin Co., Ltd.

Phase 3 Completed
139 enrolled 7 charts

Neoplasms, Pain, Breakthrough Pain

NCT05037539 2022-08-31

Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain

Department of Medical Services Ministry of Public Health of Thailand

Phase 1/2 Completed
20 enrolled

Breakthrough Pain

NCT02869321 2019-05-13

ANTALGIP

Central Hospital, Nancy, France

Phase 4 Completed
20 enrolled
Head & Neck

Head and Neck Neoplasms, Breakthrough Pain

NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236145 2013-01-29

Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed

Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡